Search

Author/Creator Ziegelbauer, Karl

1. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models. Issue 2 (20th October 2016)

Authors:
Politz, Oliver; Siegel, Franziska; Bärfacker, Lars; Bömer, Ulf; Hägebarth, Andrea; Scott, William J.; Michels, Martin; Ince, Stuart; Neuhaus, Roland; Meyer, Kirstin; Fernández‐Montalván, Amaury Ernesto; Liu, Ningshu; von Nussbaum, Franz; Mumberg, Dominik; Ziegelbauer, Karl
Journal:
International journal of cancer
Issue:
Volume 140:Issue 2(2017:Jan. 15)
Page Start:
449
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. BAY 87‐2243, a highly potent and selective inhibitor of hypoxia‐induced gene activation has antitumor activities by inhibition of mitochondrial complex I. (20th August 2013)

Authors:
Ellinghaus, Peter; Heisler, Iring; Unterschemmann, Kerstin; Haerter, Michael; Beck, Hartmut; Greschat, Susanne; Ehrmann, Alexander; Summer, Holger; Flamme, Ingo; Oehme, Felix; Thierauch, Karlheinz; Michels, Martin; Hess‐Stumpp, Holger; Ziegelbauer, Karl
Journal:
Cancer medicine
Issue:
Volume 2:Number 5(2013:Oct.)
Page Start:
611
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. (16th October 2017)

Authors:
Lücking, Ulrich; Scholz, Arne; Lienau, Philip; Siemeister, Gerhard; Kosemund, Dirk; Bohlmann, Rolf; Briem, Hans; Terebesi, Ildiko; Meyer, Kirstin; Prelle, Katja; Denner, Karsten; Bömer, Ulf; Schäfer, Martina; Eis, Knut; Valencia, Ray; Ince, Stuart; von Nussbaum, Franz; Mumberg, Dominik; Ziegelbau...
Journal:
ChemMedChem
Issue:
Volume 12:Number 21(2017)
Page Start:
1776
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Knockdown of platinum‐induced growth differentiation factor 15 abrogates p27‐mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis. (10th December 2014)

Authors:
Meier, Julia C.; Haendler, Bernard; Seidel, Henrik; Groth, Philip; Adams, Robert; Ziegelbauer, Karl; Kreft, Bertolt; Beckmann, Georg; Sommer, Anette; Kopitz, Charlotte
Journal:
Cancer medicine
Issue:
Volume 4:Number 2(2015:Feb.)
Page Start:
253
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XI. Issue 11 (November 2019)

Authors:
Georgi, Benjamin; Mielke, Johanna; Chaffin, Mark; Khera, Amit V.; Gelis, Lian; Mundl, Hardi; van Giezen, J.J.J.; Ellinor, Patrick; Kathiresan, Sekar; Ziegelbauer, Karl; Freitag, Daniel F.
Journal:
Stroke
Issue:
Volume 50:Issue 11(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models. Issue 5 (13th March 2019)

Authors:
Grünewald, Sylvia; Politz, Oliver; Bender, Sebastian; Héroult, Mélanie; Lustig, Klemens; Thuss, Uwe; Kneip, Christoph; Kopitz, Charlotte; Zopf, Dieter; Collin, Marie‐Pierre; Boemer, Ulf; Ince, Stuart; Ellinghaus, Peter; Mumberg, Dominik; Hess‐Stumpp, Holger; Ziegelbauer, Karl
Journal:
International journal of cancer
Issue:
Volume 145:Issue 5(2019)
Page Start:
1346
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗